Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors –α/γ dual agonists for treatment of metabolic disorders

References

• Bénardeau, A., Benz, J., Binggeli , A., Blum, D., Boehringer, M., Grether, U., … Mohr, P. (2009). Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorganic and Medicinal Chemistry Letters, 19(9), 2468–2473. doi:10.1016/j.bmcl.2009.03.036
   PubMed Web of Science ®Google Scholar
• Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005). PPARs: Therapeutic targets for metabolic disease. Trends in Pharmacological Sciences, 26(5), 244–251. doi:10.1016/j.tips.2005.03.003
   PubMed Web of Science ®Google Scholar
• Boda, K., Seidel, T., & Gasteiger, J. (2007). Structure and reaction based evaluation of synthetic accessibility. Journal of Computer-Aided Molecular Design, 21(6), 311–325. doi:10.1007/s10822-006-9099-2
   PubMed Web of Science ®Google Scholar
• Bowers, K. J., Chow, E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., & Shaw, D. E. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters, Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), 11–17. doi:10.1109/SC.2006.54
   Google Scholar
• Casimiro-Garcia, A., Bigge, C. F., Davis, J. A., Padalino, T., Pulaski, J., Ohren, J. F., … Song, K. (2009). Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists. Bioorganic and Medicinal Chemistry, 17(20), 7113–7125. doi:10.1016/j.bmc.2009.09.001
   PubMed Web of Science ®Google Scholar
• Cronet, P., Petersen, J. F. W., Folmer, R., Blomberg, N., Sjöblom, K., Karlsson, U., … Bamberg, K. (2001). Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure, 9(8), 699–706. doi:10.1016/S0969-2126(01)00634-7
   PubMed Web of Science ®Google Scholar
• De Rosa, S., Arcidiacono, B., Chiefari, E., Brunetti, A., Indolfi, C., & Foti, D. P. (2018). Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links. Frontiers in Endocrinology, 9(2), 1–13. doi:10.3389/fendo.2018.00002
   Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion Drug Discovery, 10(5), 449–461. doi:10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Gervois, P., Fruchart, J.-C., & Staels, B. (2007). Drug Insight: Mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nature Clinical Practice Endocrinology & Metabolism, 3(2), 145–156. doi:10.1038/ncpendmet0397
   PubMedGoogle Scholar
• Gilardi, F., Giudici, M., Mitro, N., Maschi, O., Guerrini, U., Rando, G., … Crestani, M. (2014). LT175 is a novel PPARα/β ligand with potent insulin-sensitizing effects and reduced adipogenic properties. Journal of Biological Chemistry, 289(10), 6908–6920. doi:10.1074/jbc.M113.506394
   PubMed Web of Science ®Google Scholar
• Halgren, T. (2007). New method for fast and accurate binding-site identification and analysis. Chemical Biology & Drug Design, 69(2), 146–148. doi:10.1111/j.1747-0285.2007.00483.x
   PubMed Web of Science ®Google Scholar
• Huang, Z., & Wong, C. F. (2016). Inexpensive method for selecting receptor structures for virtual screening. Journal of Chemical Information and Modeling, 56(1), 21–34. doi:10.1021/acs.jcim.5b00299
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. doi:10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• Kawatkar, S., Wang, H., Czerminski, R., & Joseph-McCarthy, D. (2009). Virtual fragment screening: An exploration of various docking and scoring protocols for fragments using Glide. Journal of Computer-Aided Molecular Design, 23(8), 527–539. doi:10.1007/s10822-009-9281-4
   PubMed Web of Science ®Google Scholar
• Liu, L., Ma, Y., Wang, R. L., Xu, W. R., Wang, S. Q., & Chou, K. C. (2013). Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Drug. Drug Design, Development and Therapy, 7, 279–288. doi:10.2147/DDDT.S42113
   PubMed Web of Science ®Google Scholar
• Liu, X., Jing, Z., Jia, W. Q., Wang, S. Q., Ma, Y., Xu, W. R., … Cheng, X. C. (2018). Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 36(11), 2988–3002. doi:10.1080/07391102.2017.1373706
   PubMed Web of Science ®Google Scholar
• Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. doi:10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Malik, R., Bunkar, D., Choudhary, B. S., Srivastava, S., Mehta, P., & Sharma, M. (2016). High throughput virtual screening and in silico ADMET analysis for rapid and efficient identification of potential PAP248-286aggregation inhibitors as anti-HIV agents. Journal of Molecular Structure, 1122, 239–246. doi:10.1016/j.molstruc.2016.05.086
   Web of Science ®Google Scholar
• Malik, R., Mehta, P., Srivastava, S., Choudhary, B., & Sharma, M. (2017). Structure-based screening, ADMET profiling, and molecular dynamic studies on mGlu2 receptor for identification of newer antiepileptic agents. Journal of Biomolecular Structure and Dynamics, 35(16), 3433–3448. doi:10.1080/07391102.2016.1257440
   PubMed Web of Science ®Google Scholar
• Merk, D., Lamers, C., Weber, J., Flesch, D., Gabler, M., Proschak, E., & Schubert-Zsilavecz, M. (2015). Anthranilic acid derivatives as nuclear receptor modulators—Development of novel PPAR selective and dual PPAR/FXR ligands. Bioorganic and Medicinal Chemistry, 23(3), 499–514. doi:10.1016/j.bmc.2014.12.013
   Web of Science ®Google Scholar
• Nath, V., Ahuja, R., & Kumar, V. (2018a). Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid in silico-screening techniques and molecular dynamics simulations thereof. Journal of Biomolecular Structure and Dynamics, 1–24. doi:10.1080/07391102.2018.1527255
   PubMed Web of Science ®Google Scholar
• Nath, V., Ahuja, R., & Kumar, V. (2018b). Virtual screening and in silico simulation analysis for rapid and efficient identification of novel natural GPR40 agonist. Letters in Drug Design & Discovery, 15, 1–13. doi:10.2174/1570180815666180914162935
   Google Scholar
• Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., … Milburn, M. V. (1998). Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature, 395(6698), 137–143. doi:10.1038/25931
   PubMed Web of Science ®Google Scholar
• Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A. C., & Villoutreix, B. O. (2010). Druggable pockets and binding site centric chemical space: A paradigm shift in drug discovery. Drug Discovery Today, 15(15–16), 656–667. doi:10.1016/j.drudis.2010.05.015
   PubMed Web of Science ®Google Scholar
• Shaw, D. E., Maragakis, P., Lindorff-Larsen, K., Piana, S., Dror, R. O., Eastwood, M. P., … Wriggers, W. (2010). Atomic-level characterization. Science, 330(6002), 341–346. doi:10.1126/science.1187409
   PubMed Web of Science ®Google Scholar
• Sirin, S., Kumar, R., Martinez, C., Karmilowicz, M. J., Ghosh, P., Abramov, Y. A., … Sherman, W. (2014). A computational approach to enzyme design: Predicting W-Aminotransferase catalytic activity using docking and MM-GBSA scoring. Journal of Chemical Information and Modeling, 54(8), 2334–2346. doi:10.1021/ci5002185
   PubMed Web of Science ®Google Scholar
• Sotriffer, C., & Klebe, G. (2002). Identification and mapping of small-molecule binding sites in proteins: Computational tools for structure-based drug design. Farmaco, 57(3), 243–251. doi:10.1016/S0014-827X(02)01211-9
   PubMedGoogle Scholar
• Srivastava, S., Singh Choudhary, B., Mehta, P., Sukanya, Sharma, M., & Malik, R. (2018). Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors. Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2018.1489304
   Google Scholar
• Ta, H. (2009). Identifying and characterizing binding sites and assessing druggability. Journal of Chemical Information and Modeling, 49(2), 377–389.
   PubMed Web of Science ®Google Scholar
• Vyas, V. K., Ghate, M., & Goel, A. (2013). Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Journal of Molecular Graphics and Modelling, 42, 17–25. doi:10.1016/j.jmgm.2013.01.010
   PubMed Web of Science ®Google Scholar
• Zhang, J., Liu, X., Xie, X. B., Cheng, X. C., & Wang, R. L. (2016). Multitargeted bioactive ligands for PPARs discovered in the last decade. Chemical Biology & Drug Design, 88(5), 635–663. doi:10.1111/cbdd.12806
   PubMed Web of Science ®Google Scholar